Financing co-led by Forbion and Population Health Partners
-
Dosing initiated in Phase 1 clinical trial of COR-1004, a novel PCSK9 siRNA
Naarden, The Netherlands, 7 January 2026 – Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that it has co-led an over-subscribed $80 million Series A financing in Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention. Population Health Partners co-led the financing, which included participation from other leading investors, including Corsera Co-Founder and Co-CEO John Maraganore, Ph.D. In connection with the Series A financing, Marco Boorsma, Ph.D., General Partner at Forbion, will join the board of directors of Corsera Health. The proceeds will fund the company’s approach to extending healthspan, by empowering individuals to understand and reduce their risk of atherosclerotic cardiovascular disease (ASCVD). Corsera also announced the initiation of dosing in a Phase 1 clinical trial of COR-1004, a novel subcutaneously administered siRNA targeting PCSK9.
Corsera Health exemplifies the kind of bold, science-driven innovation that Forbion aims to support and scale. The company’s integrated approach, combining durable RNAi therapeutics with advanced predictive technology, has the potential to fundamentally shift cardiovascular care from late intervention to true prevention. The Corsera team brings exceptional scientific depth, drug development expertise, and a clear vision for global impact. We are excited to partner closely with the company, as it advances toward clinical validation and builds a category-defining cardiovascular prevention platform.”
Marco Boorsma, PhD
General Partner
“With this financing and the start of our first clinical trial, we are entering a pivotal next phase for the company,” said John Maraganore, Ph.D., Co-Founder and Co-CEO of Corsera Health. “By combining AI-enabled prediction of lifetime ASCVD risk with preventive RNAi medicines, Corsera has the potential to change the trajectory of cardiovascular disease, enabling earlier intervention and broad access to prevention at a population scale.”
“At Corsera, we are motivated by a bold vision: a world without cardiovascular disease. We are making strong progress toward a future in which preventive care enables people to live longer, healthier lives, and the initiation of our first clinical trial marks an important milestone on that journey,” said Clive Meanwell, M.D., Co-Founder and Co-CEO of Corsera Health and Managing Partner of Population Health Partners.
The financing will support advancement of Corsera Health’s preventive RNAi medicine program, which targets the two primary drivers of cardiovascular disease: low-density lipoprotein cholesterol (LDL-C) and blood pressure. The funding will also support continued development of Klotho, Corsera Health’s proprietary AI-enabled precision health platform, which is designed to predict lifetime cardiovascular disease risk and quantify the potential benefit of lowering LDL-C and blood pressure to extend cardiovascular healthspan.
***ENDS***
About Corsera Health
Corsera Health aims to lead the future of medicine by extending healthspan through cardiovascular disease prediction and prevention. Co-founded by industry pioneers in RNAi therapeutics and cardiovascular medicine, the company is combining decades of innovation in RNAi therapeutics with world-leading expertise in cardiovascular disease prediction, efficient manufacturing and evidence generation, and disruptive commercialization. Corsera Health is headquartered in Boston, Mass. For more information, please visit us at www.corserahealth.com and follow us on LinkedIn and X.
About Forbion
Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.
